Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis

NCT03654755 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

162

Enrollment

INDUSTRY

Sponsor class

Stopped Phase 2 study results

Conditions

Atopic Dermatitis

Interventions

DRUG: ASN002

Sponsor

Asana BioSciences